Position in ABVX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$150,924,545
New position
Shares Held
1,132,557
first reported quarter
Ownership
1.30%
of shares outstanding
% of Portfolio
1.33%
of 13F equity value
Holder Rank
#12
of 301 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026RA CAPITAL MANAGEMENT, L.P. holds $11,082,969,028 across 75 Biotechnology names. ABVX ranks #20 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
10,281,496 | $2,742,280,613 | |
| 2 | PBLS |
Parabilis Medicines, Inc.
|
28,933,371 | $791,906,364 | |
| 3 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
6,666,837 | $740,218,912 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
11,474,599 | $667,018,439 | |
| 5 | SION |
Sionna Therapeutics, Inc.
|
9,905,045 | $435,722,929 | |
| 6 | TYRA |
Tyra Biosciences, Inc.
|
12,198,625 | $389,624,082 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
8,392,730 | $340,996,619 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
9,883,524 | $330,779,298 |
All Filings in ABVX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $150,924,545 | 1,132,557 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||